On Wednesday, FreeSeas Inc (NASDAQ:FREE)’s shares declined -11.35% to $2.50.
FreeSeas Inc (FREE) through the ownership and operation of a fleet of Handysize vessels declared recently that it has attained a 51% controlling stake in the newly formed Standcorp International Limited. The rest of the shares are owned by non-associated entities associated with the Marvin group of companies, whose extensive experience for over twenty years has focused in the operation and ownership of tanker vessels. Standcorp will engage in the commercial operation of product and crude oil tankers covering a large array of sizes, by contracting them through time charter or bareboat charter arrangements, and subsequently deploying them in the spot market or in fulfillment of contract cargoes. The company intends to operate in generic markets but also to focus on a number of niche markets, such as West Africa. In addition, the company shall, depending on market conditions, commercially operate dry-bulk carriers either chartered-in, attained, or through services agreements with associated Owners, counting FreeSeas Inc. tonnage.
FreeSeas Inc., through its auxiliaries, provides drybulk shipping services. Its vessels carry various drybulk commodities, such as iron ore, grain, and coal, in addition to bauxite, phosphate, fertilizers, steel products, cement, sugar, and rice. Its fleet comprises of five Handysize vessels and one Handymax vessel. As of April 23, 2015, its operational fleet had about 148,978 deadweight tons with the average age of 17.7 years
New Senior Investment Group Inc (NYSE:SNR)’s shares dropped -0.52% to $13.48.
New Senior Investment Group Inc. (SNR) declared that it will release its second quarter 2015 financial results on Thursday, August 6, 2015 preceding to the opening of trading on the New York Stock Exchange. A copy of the press release will be posted to the Investor Relations section of New Senior’s website, www.newseniorinv.com.
New Senior Investment Group Inc. (NYSE:SNR.WI) operates independently of Newcastle Investment Corp. as of November 6, 2014.
At the end of Wednesday’s trade, BlackRock, Inc. (NYSE:BLK)‘s shares surged 1.12% to $346.58.
With U.S. monetary policy turning, fundamentals such as productivity and earnings growth are poised to regain prominence as drivers of investment return - with some key indicators “flashing red,” according to BlackRock (BLK) Investment Institute’s (BII) mid-year 2015 investment outlook.
The mid-year outlook, “Nearing Normal,” provides an update on BII’s main economic assumptions and top investment ideas for 2015, a year so far characterized by divergence in global central bank monetary policy and asset prices.
BlackRock, Inc. is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors. It also manages accounts for corporate, public, union and industry pension plans, insurance companies, third-party mutual funds, endowments, foundations, charities, corporations, official institutions, and banks.
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), ended its Wednesday’s trading session with -0.56% loss, and closed at $1.78.
Navidea Biopharmaceuticals, Inc. (NAVB) and its partner, Macrophage Therapeutics, Inc., will hold a post-International Workshop on Kaposi’s Sarcoma Herpesvirus (KSHV) and Related Agents conference webcast to provide investors with a more detailed look at the recently presented Manocept™ platform clinical and pre-clinical data and results revealed in recently’s press releases. The webcast will take place on July 7, 2015 at 1:00 pm EDT. Rick Gonzalez, Navidea’s CEO and Michael Goldberg, M.D., Macrophage Therapeutics’ CEO will host the call along with Michael S. McGrath, M.D., Ph.D., Professor, Departments of Laboratory Medicine, Pathology, and Medicine at the University of California, San Francisco who will talk about the data presented.
Navidea Biopharmaceuticals, Inc., a precision medicine company, focuses on the development and commercialization of precision diagnostics, therapeutics, and radiopharmaceutical agents. The company offers Lymphoseek Injection, a receptor-targeted small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients; and Manocept platform to target the CD206 mannose receptor expressed on macrophages.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
